BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 31694820)

  • 1. Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis.
    Aboian MS; Tong E; Solomon DA; Kline C; Gautam A; Vardapetyan A; Tamrazi B; Li Y; Jordan CD; Felton E; Weinberg B; Braunstein S; Mueller S; Cha S
    AJNR Am J Neuroradiol; 2019 Nov; 40(11):1804-1810. PubMed ID: 31694820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive assessment of H3 K27M mutational status in diffuse midline gliomas by using apparent diffusion coefficient measurements.
    Chen H; Hu W; He H; Yang Y; Wen G; Lv X
    Eur J Radiol; 2019 May; 114():152-159. PubMed ID: 31005167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation.
    Aboian MS; Solomon DA; Felton E; Mabray MC; Villanueva-Meyer JE; Mueller S; Cha S
    AJNR Am J Neuroradiol; 2017 Apr; 38(4):795-800. PubMed ID: 28183840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
    Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of diffuse midline glioma, H3 K27M mutant mimicking a hemispheric malignant glioma in an elderly patient.
    Fujioka Y; Hata N; Hatae R; Suzuki SO; Sangatsuda Y; Nakahara Y; Mizoguchi M; Iihara K
    Neuropathology; 2020 Feb; 40(1):99-103. PubMed ID: 31762138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
    Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
    J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H3 K27M-mutant diffuse midline gliomas in different anatomical locations.
    Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D
    Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3 K27M Mutant Diffuse Midline Glioma.
    Hohm A; Karremann M; Gielen GH; Pietsch T; Warmuth-Metz M; Vandergrift LA; Bison B; Stock A; Hoffmann M; Pham M; Kramm CM; Nowak J
    Clin Neuroradiol; 2022 Mar; 32(1):249-258. PubMed ID: 34919158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of H3 K27M-mutant gliomas in adults.
    Meyronet D; Esteban-Mader M; Bonnet C; Joly MO; Uro-Coste E; Amiel-Benouaich A; Forest F; Rousselot-Denis C; Burel-Vandenbos F; Bourg V; Guyotat J; Fenouil T; Jouvet A; Honnorat J; Ducray F
    Neuro Oncol; 2017 Aug; 19(8):1127-1134. PubMed ID: 28201752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of H3 K27M mutations in adult midline gliomas.
    Ebrahimi A; Skardelly M; Schuhmann MU; Ebinger M; Reuss D; Neumann M; Tabatabai G; Kohlhof-Meinecke P; Schittenhelm J
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):839-850. PubMed ID: 30610375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
    Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
    Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep Learning for Noninvasive Assessment of H3 K27M Mutation Status in Diffuse Midline Gliomas Using MR Imaging.
    Li J; Zhang P; Qu L; Sun T; Duan Y; Wu M; Weng J; Li Z; Gong X; Liu X; Wang Y; Jia W; Su X; Yue Q; Li J; Zhang Z; Barkhof F; Huang RY; Chang K; Sair H; Ye C; Zhang L; Zhuo Z; Liu Y
    J Magn Reson Imaging; 2023 Sep; 58(3):850-861. PubMed ID: 36692205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiation between spinal cord diffuse midline glioma with histone H3 K27M mutation and wild type: comparative magnetic resonance imaging.
    Jung JS; Choi YS; Ahn SS; Yi S; Kim SH; Lee SK
    Neuroradiology; 2019 Mar; 61(3):313-322. PubMed ID: 30662997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodal MR imaging signatures to identify brain diffuse midline gliomas with H3 K27M mutation.
    Su X; Liu Y; Wang H; Chen N; Sun H; Yang X; Wang W; Zhang S; Wan X; Tan Q; Yue Q; Gong Q
    Cancer Med; 2022 Feb; 11(4):1048-1058. PubMed ID: 34953060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
    Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
    J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric Diffuse Midline Gliomas H3 K27M-Mutant and Non-Histone Mutant Midline High-Grade Gliomas in Neurofibromatosis Type 1 in Comparison With Non-Syndromic Children: A Single-Center Pilot Study.
    Garibotto F; Madia F; Milanaccio C; Verrico A; Piccardo A; Tortora D; Piatelli G; Diana MC; Capra V; Garrè ML; Rossi A; Morana G
    Front Oncol; 2020; 10():795. PubMed ID: 32582540
    [No Abstract]   [Full Text] [Related]  

  • 18. Differences in the MRI Signature and ADC Values of Diffuse Midline Gliomas with H3 K27M Mutation Compared to Midline Glioblastomas.
    Raab P; Banan R; Akbarian A; Esmaeilzadeh M; Samii M; Samii A; Bertalanffy H; Lehmann U; Krauss JK; Lanfermann H; Hartmann C; Brüning R
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman.
    Low JT; Wang SH; B Peters K
    CNS Oncol; 2021 Jun; 10(2):CNS71. PubMed ID: 33908265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tectal Low-Grade Glioma with H3 K27M Mutation.
    Sumi K; Shijo K; Igarashi T; Yamamuro S; Sasano M; Oshima H; Ishige T; Honma T; Yagasaki H; Yoshino A
    World Neurosurg; 2020 Sep; 141():91-100. PubMed ID: 32505657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.